Abstract
Multimodal therapy is currently the standard of care for EGJ cancer. In particular, induction chemo-radiation is widely accepted as the standard in Siewert I and II cancers, while peri-operative or induction chemotherapy is the preferred approach in Siewert III. Patients’ survival is strictly related to the grade of response to preoperative therapy: indeed, it is well known that patients with pathological complete response show a higher survival rate compared to nonresponders. Anyway, between these two extremes, there is a group of patients who respond to neo-adjuvant therapy but still have residual disease: the prognosis of this group of patients is more difficult to predict.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ishwaran H, Blackstone EH, Apperson-Hansen C, Rice TW (2009) A novel approach to cancer staging: application to esophageal cancer. Biostatistics 10(4):603–620
Mehta SP, Jose P, Mirza A et al (2013) Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery. Dis Esophagus 26(2):182–188
Schmidt T, Sicic L, Blank S et al (2013) Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014:1–9
Mandard AM, Dalibard F, Mandard JC, Marnay J et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686
Verlato G, Zanoni A, Tomezzoli A et al (2010) Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumor regression grade or size of residual foci. Br J Surg 97(5):719–725
Swisher SG, Hofstetter W, Wu TT et al (2005) Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810–817; discussion 817–820
Schneider PM, Baldus SE, Metzger R et al (2005) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242(5):684–692
Hölscher AH, Drebber U, Schmidt H et al (2014) Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg 260(5):779–785
Zanoni A, Verlato G, Giacopuzzi S et al (2012) Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Ann Surg Oncol 20(6):1993–1999
Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530
Becker K, Langer R, Reim D et al (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934–939
Sano T, Kodera Y (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14(2):101–112
Nakamura K, Kuwata T, Shimoda T et al (2015) Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer 18(3):597–604
Cunningham D, Allum WH, Stenning SP et al (2005) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. World Health 355(1):877–889
Becker K, Reim D, Novotny A et al (2012) Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 256(6):1002–1007
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Zanoni, A., Giacopuzzi, S., Tomezzoli, A., Bencivenga, M., de Manzoni, G. (2017). Pathological Response to Neoadjuvant Treatment: More Questions Than Answers. In: Giacopuzzi, S., Zanoni, A., de Manzoni, G. (eds) Adenocarcinoma of the Esophagogastric Junction. Springer, Cham. https://doi.org/10.1007/978-3-319-28776-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-28776-8_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28774-4
Online ISBN: 978-3-319-28776-8
eBook Packages: MedicineMedicine (R0)